Peptide Schedule
FOXO4-DRI17 residuesLTLRKEPASEIAQSILEEach bubble = one amino acid. Size = residue mass. Color = chemical class.FOXO4-DRI
Benefits
About FOXO4-DRI
FOXO4-DRI is a D-retro-inverso peptide engineered to selectively eliminate senescent cells — often called "zombie cells" — that accumulate with age and drive chronic inflammation, tissue deterioration, and age-related disease. It was developed by Peter de Keizer and colleagues at Erasmus University Medical Center in the Netherlands and first described in a 2017 Cell paper. The peptide works by disrupting the interaction between FOXO4 and p53, two proteins that together keep senescent cells alive. When FOXO4-DRI breaks this interaction, p53 is excluded from the nucleus and redirected to the mitochondria, where it triggers apoptosis exclusively in senescent cells while leaving healthy cells unaffected. In preclinical mouse studies, FOXO4-DRI treatment reversed age-related fitness decline, restored fur density, and normalized kidney function markers (plasma urea and creatinine). It also cleared chemotherapy-induced senescent cells. Because FOXO4-DRI uses D-amino acids in a reversed sequence (the retro-inverso approach), it resists protease degradation better than standard L-peptides, giving it improved stability. However, this same property makes it difficult and expensive to synthesize, and no human clinical trials have been completed to date. All dosing information is extrapolated from animal studies and anecdotal protocols — there is no established safe or effective human dose. Researchers continue to study FOXO4-DRI and related senolytic peptides as potential tools for addressing aging at the cellular level, but anyone considering this compound should understand that it remains firmly in the experimental research stage.
Who Should Consider FOXO4-DRI
- Researchers studying cellular senescence and aging biology
- Adults interested in experimental longevity interventions (with full informed consent)
- Individuals with high senescent cell burden from chemotherapy or radiation (research context)
- Aging adults experiencing accelerated tissue decline (preclinical rationale only)
- Not suitable for the general population — preclinical compound with no human safety data
How FOXO4-DRI Works
FOXO4-DRI is a cell-permeable D-retro-inverso peptide derived from the p53-interaction domain of FOXO4. In senescent cells, FOXO4 is upregulated and binds directly to p53 in the nucleus, sequestering p53 and preventing it from initiating apoptosis. This FOXO4-p53 interaction is what keeps senescent cells alive despite their damaged state. FOXO4-DRI competes with endogenous FOXO4 for binding to p53, displacing FOXO4 from the complex. Once freed, phosphorylated p53 is excluded from the nucleus and translocates to the mitochondria, where it activates the intrinsic apoptosis pathway — triggering BAX activation and caspase-3 cleavage, which leads to programmed cell death. Because FOXO4 is selectively upregulated in senescent cells (not in healthy, proliferating cells), this mechanism targets only damaged cells while leaving normal tissue intact. The D-retro-inverso design uses D-amino acids arranged in reverse order, producing a peptide that mimics the binding surface of the original L-peptide but resists enzymatic degradation by proteases.
What to Expect
Initial dosing phase. No immediate visible effects expected. Senescent cell apoptosis begins at the cellular level. Mild injection site reactions possible. Some users report transient flu-like symptoms as senescent cells are cleared.
Continued senolytic clearance during on-cycle. Inflammatory markers may transiently rise as senescent cells undergo apoptosis and are removed by the immune system. Energy levels and general well-being may begin to shift, though individual responses are highly variable.
Post-cycle recovery and tissue remodeling. The body processes debris from cleared senescent cells. In mouse models, functional improvements (activity, organ function) became apparent during this phase. Any benefits in humans remain unconfirmed.
Extended off-period allows full tissue adaptation. In animal studies, improvements in kidney function and physical fitness persisted well beyond the treatment window. Biomarker reassessment recommended before considering another cycle.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 500mcg | 3x/week |
| Moderate | 1mg | 3x/week |
| Aggressive | 3mg | EOD |
Note: D-retro-inverso senolytic peptide. Preclinical only — no human trials completed. Extremely expensive due to synthesis complexity. Disrupts FOXO4-p53 interaction in senescent cells. Developed by Peter de Keizer at Erasmus MC. Run in short pulsed cycles with extended off-periods.
How to Inject FOXO4-DRI
Inject subcutaneously, rotating sites between abdomen, outer thigh, and upper arm. Administer on non-consecutive days (e.g., Monday, Wednesday, Friday) during on-cycle weeks to allow senescent cell apoptosis between doses. Reconstitute gently — do not shake. Due to the complete lack of human clinical data, start at the lowest possible dose and titrate cautiously. Monitor for any adverse reactions including injection site inflammation and systemic flu-like symptoms.
Cycling Protocol
Short pulsed cycles are typical — 2-3 weeks of injections followed by 3-4 months off to allow full senescent cell clearance and tissue remodeling. Some protocols use 3 consecutive injection days per week during the on-cycle. Biomarker assessment (inflammatory markers, kidney function) recommended before repeating. Most anecdotal protocols suggest 1-3 cycles per year at most.
Pharmacokinetics
Source: Estimated from peptide pharmacokinetics; D-retro-inverso form extends duration vs. L-peptide. No direct human PK studies available.
Loading the interactive decay curve.
Side Effects
No human clinical safety data exists. In animal studies, FOXO4-DRI was generally well-tolerated. Potential risks include injection site reactions, transient flu-like symptoms from senescent cell clearance (senolytic response), and unknown off-target effects. The large-scale clearance of senescent cells could theoretically cause inflammatory responses. Long-term safety in humans is entirely uncharacterized.
Contraindications
- Pregnancy or breastfeeding — no reproductive safety data exists
- Active autoimmune disease — senolytic clearance may unpredictably modulate immune responses
- Immunocompromised individuals — clearance of apoptotic cells requires functional immune system
- Active cancer — p53 pathway manipulation could have unpredictable effects on tumor biology
- Severe hepatic or renal impairment — impaired clearance of cellular debris
- Known hypersensitivity to FOXO4-DRI or any excipients
- Children and adolescents — cellular senescence plays different roles during development
Drug Interactions
- Immunosuppressants (cyclosporine, tacrolimus, methotrexate) — may impair clearance of apoptotic senescent cells
- Chemotherapy agents — concurrent use could cause excessive senescent cell burden and amplified senolytic response
- Anticoagulants (warfarin, heparin) — theoretical risk of altered bleeding due to vascular senescent cell clearance
- Other senolytic compounds (dasatinib, quercetin, navitoclax) — overlapping mechanisms may cause excessive apoptosis
- p53-modulating drugs (nutlins, MDM2 inhibitors) — direct pathway overlap could amplify or interfere with FOXO4-DRI effects
Storage & Stability
Molecular Profile
Related Peptides
References
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and AgingPubMed 28340339
- Regulation of cellular senescence via the FOXO4-p53 axisReview
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human ChondrocytesPubMed 34045925
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged micePubMed
- Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cellsPubMed